- Home
- SMTI vs CLLS Comparison
SMTI vs CLLS Comparison
Compare SMTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMTI | CLLS |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.9M | 299.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | SMTI | CLLS |
|---|---|---|
| Price | $25.25 | $4.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $41.00 | $8.00 |
| AVG Volume (30 Days) | 52.0K | ★ 147.2K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,877,532.00 | $82,551,000.00 |
| Revenue This Year | $21.60 | $32.58 |
| Revenue Next Year | $16.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 30.52 | ★ 129.04 |
| 52 Week Low | $18.90 | $1.10 |
| 52 Week High | $38.68 | $5.48 |
Technical Indicators
Market Signals| Indicator | SMTI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 42.87 |
| Support Level | $20.06 | $4.47 |
| Resistance Level | $27.00 | $5.45 |
| Average True Range (ATR) | 1.28 | 0.30 |
| MACD | 0.83 | -0.09 |
| Stochastic Oscillator | 75.65 | 9.09 |
Price Performance
Historical ComparisonAbout SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.